Rogério Vivaldi Coelho
About Rogério Vivaldi Coelho
Rogério Vivaldi Coelho, M.D., age 61, has served as an independent director of Crinetics since January 2022. A physician with an MBA, he has 20+ years of rare disease and biopharma leadership spanning Genzyme, Spark Therapeutics, Bioverativ, and Sigilon Therapeutics, with deep commercialization and global market access experience. He completed an endocrinology residency in Brazil and a genetics fellowship at Mount Sinai focused on Gaucher disease, and later became the first physician in Brazil to use enzyme replacement therapy for Gaucher patients .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Sigilon Therapeutics, Inc. | President, CEO and Director | Retired Dec 2023 | Led company; board-level oversight |
| Bioverativ Inc. | EVP & Chief Global Therapeutics Officer | 2016–2018 | Built commercial org; led sales/marketing; until acquisition by Sanofi |
| Spark Therapeutics, Inc. | Chief Commercial Officer | 2014–2016 | Launched global commercial ops; advocacy, market access, medical affairs for Luxturna |
| Genzyme | Multiple senior roles: President (Rare Disease; Renal & Endocrine), SVP & GM Latin America | ~20 years through 2010s | Led >15 orphan product approvals in >20 countries |
| Academic/Training | MD (Universidade do Rio de Janeiro), Endocrinology Residency (UERJ), Genetics Fellowship (Mount Sinai) | — | First in Brazil to treat Gaucher with enzyme replacement therapy |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Sigilon Therapeutics, Inc. | Director | Retired Dec 2023 | Former public company board role |
No other current public company directorships are disclosed for Dr. Vivaldi in Crinetics’ proxy .
Board Governance
- Board class: Class I director; nominee for a term expiring at 2028 annual meeting .
- Independence: Board determined he is independent under SEC/Nasdaq; audit committee confirms independence and financial literacy .
- Attendance: In 2024, each director attended at least 75% of board and applicable committee meetings; board met 4 times .
- Committees (2024):
- Audit Committee: Member; 4 meetings; chair is Matthew K. Fust .
- Research & Development Committee: Member; 4 meetings; chair is Dr. Bedrosian .
- Global Therapeutics Strategy & Access Committee: Chair; established Sep 2024; met once in 2024 .
Fixed Compensation
Director compensation program (effective June 7, 2024):
| Component | Amount ($) | Notes |
|---|---|---|
| Annual cash retainer (non‑employee directors) | 41,000 | Program adopted after Aon review |
| Chair of Board (additional) | 30,000 | — |
| Committee chair retainers | Audit $20,000; Compensation $15,000; Nominating & Governance $10,000; R&D $15,000 | — |
| Committee member (non‑chair) retainers | Audit $10,000; Compensation $7,500; Nominating & Governance $5,000; R&D $7,500 | — |
| Initial equity (upon appointment) | Options $525,000; RSUs $225,000 | Vests over 3 years, in equal annual installments |
| Annual equity (for continuing directors) | Options $350,000; RSUs $150,000 | Vests at first anniversary or next annual meeting |
| Annual limit on director compensation | $750,000 (normal); $1,000,000 (initial year) | Per 2018 Plan; exceptions allowed in extraordinary circumstances |
2024 actual compensation (non‑employee director):
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Total ($) |
|---|---|---|---|---|
| Rogério Vivaldi Coelho, M.D. | 58,000 | 152,014 | 341,750 | 551,764 |
Performance Compensation
Annual director equity design and vesting:
| Grant Type | Annual Value ($) | Vesting | Notes |
|---|---|---|---|
| Options (Annual) | 350,000 | Vests on earlier of 1-year anniversary or next annual meeting | Time‑based; performance metrics not specified for director grants |
| RSUs (Annual) | 150,000 | Same as above | Time‑based |
| Options (Initial) | 525,000 | 3 equal annual installments over 3 years | Time‑based |
| RSUs (Initial) | 225,000 | 3 equal annual installments over 3 years | Time‑based |
Outstanding equity (as of Dec 31, 2024):
| Security | Count |
|---|---|
| RSUs outstanding | 3,400 |
| Options outstanding | 73,750 |
Performance metrics tied to director compensation:
| Metric Type | Disclosure |
|---|---|
| Quantitative performance conditions | None disclosed; director equity is time‑based vesting |
Other Directorships & Interlocks
- Compensation committee interlocks: None. No member of Crinetics’ compensation committee served as a Crinetics officer; no CRNX executive served on boards or compensation committees of entities with executives on CRNX’s compensation committee .
Expertise & Qualifications
- Medical and scientific: MD; endocrinology residency; genetics fellowship (Gaucher focus); first physician in Brazil to use enzyme replacement therapy for Gaucher .
- Commercial leadership: Built commercialization/orgs at Spark and Bioverativ; led >15 orphan approvals at Genzyme across >20 countries .
- Financial literacy: Audit committee states all members meet SEC/Nasdaq financial literacy requirements .
- MBA: COPPEAD, Universidade Federal do Rio de Janeiro .
Equity Ownership
Beneficial ownership (as of April 14, 2025):
| Holder | Shares Beneficially Owned | % of Shares Outstanding | Footnote Detail |
|---|---|---|---|
| Rogério Vivaldi Coelho, M.D. | 91,550 | <1% | Includes 14,400 common shares and 77,150 options exercisable within 60 days |
Additional alignment policies:
- Stock ownership guidelines (adopted Feb 20, 2025): Non‑employee directors must hold 3x annual cash retainer; 5 years to comply; must retain at least 50% of net shares from awards for one year after vesting until compliant; eligible securities include time‑vesting RSUs and common shares; performance RSUs count once targets are met .
- Hedging/pledging: Prohibited for directors, officers, employees (includes margining, short‑selling, puts/calls) .
Governance Assessment
- Independence and engagement: Independent director with audit committee financial literacy; participates across Audit, R&D, and chairs Global Therapeutics Strategy & Access—indicating substantive oversight of commercialization strategy; attended ≥75% of meetings in 2024 (board met 4x; audit 4x; R&D 4x; new commercialization committee met once) .
- Alignment: Director pay mixes cash retainer plus meaningful equity; standardized program with market benchmarking and capped annual plan limits; equity is time‑based (no discretionary performance metrics for directors), complemented by new ownership guidelines and anti‑hedging/pledging policy to strengthen alignment .
- Ownership: Beneficial ownership of 91,550 shares (<1%); options exercisable within 60 days total 77,150, RSUs outstanding 3,400; no pledging permitted, reducing collateralization risk .
- Conflicts/related parties: Audit committee reviews related party transactions; proxy discloses Radionetics arrangement involving CEO; no related‑party transactions involving Dr. Vivaldi are disclosed—low conflict exposure for this director .
- Shareholder sentiment: 2024 say‑on‑pay passed with ~97.3% approval, reflecting strong investor support for broader compensation governance (an indirect positive signal for board oversight quality) .